Pesquisar
BioMarin Pharmaceutical Inc
BMRNAdicionar à lista de desejos
57.590USD
-0.080-0.14%
Horário de mercado （ET）Cotações atrasadas em 15 min
11.13BValor de mercado
41.28P/L TTM
Mais detalhes de BioMarin Pharmaceutical Inc Empresa
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Informações de BioMarin Pharmaceutical Inc
Código da empresaBMRN
Nome da EmpresaBioMarin Pharmaceutical Inc
Data de listagemJul 23, 1999
CEOHardy (Alexander)
Número de funcionários3040
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 23
Endereço770 Lindaro Street
CidadeSAN RAFAEL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94901
Telefone14155066700
Sitehttps://www.biomarin.com/
Código da empresaBMRN
Data de listagemJul 23, 1999
CEOHardy (Alexander)
Executivos da empresa BioMarin Pharmaceutical Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
3.71K
-62.46%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
2.81K
-1848.04%
Mr. G. Eric Davis
Mr. G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Executive Vice President, Secretary, Chief Legal Officer
--
--
Mr. Brian R. Mueller, CPA
Mr. Brian R. Mueller, CPA
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Perguntas frequentes
Quem são os cinco principais acionistas de BioMarin Pharmaceutical Inc?
Os cinco principais acionistas de BioMarin Pharmaceutical Inc são: Mr. Richard A. (Randy) Meier
Quantas instituições possuem ações da BioMarin Pharmaceutical Inc (BMRN)?
Em 2026Q1, 1355 instituições possuíam ações da BioMarin Pharmaceutical Inc, com valor de mercado aproximado de 192.89M, representando 99.80% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -14513748.00.
Qual é a maior fonte de receita da BioMarin Pharmaceutical Inc?
Em 2026Q1, o segmento de negócios Voxzogo gerou a maior receita para BioMarin Pharmaceutical Inc, totalizando 926.92M e representando 29.26% da receita total.
